Theresa Heah is currently the CEO, Vice-Chair and Co-Founder of EYEXORA. Most recently served as the Chief Executive Officer, President and member of the Board of Directors of Paratus Sciences. Previously, she was the CEO and President of Intergalactic Therapeutics (an Apple Tree Partners company).
She brings over two decades of global leadership experience in the core business area from small molecules to biologics to gene therapies development, and commercialization in early-stage private-staged companies (Fovea Pharmaceuticals acquired by Sanofi, AsclepiX Therapeutics, Kriya Therapeutics), public-staged (Aerie Pharmaceuticals acquired by Alcon, Allergan) and big pharmaceuticals (Bayer Healthcare, Sanofi).
Theresa has led early-stage venture capital fundraising activities, companies’ creation, M&A deals and
accelerate the value creation through the addition of innovative early, mid, and late stage pipeline
candidates.
Prior to Intergalactic, she was the President and Chief Medical Officer for Kriya Therapeutics where she was responsible for launching Kriya Ophthalmology, building AAV gene therapy ophthalmology, oncology and rare disease portfolio strategy, and supporting the Series C financing of $270M. At Asclepix Therapeutics, Theresa served as Interim CEO, EVP Operations and Chief Medical Officer where she was responsible for the company formation, corporate strategy, leading the Series A financing of $35M, R&D, clinical development, and regulatory strategy to advance the robust pipeline and led the company in bringing innovative ophthalmology and oncology products to market. Dr. Heah has also served as Chief Medical Officer at AGTC (acquired by Syncona, rebranded as Beacon Therapeutics), where she led on the development of AAV gene therapies in ophthalmology, neurodegenerative and otology.
She has a diverse leadership perspective across Corporate Development, Financing Strategy, Clinical, R&D, Medical Affairs, Marketing, and Business Development. Dr. Heah led global ophthalmologic innovation with multiple successful regulatory submissions in the U.S. (7 INDs, 4 NDAs: Ozurdex, EYLEA, Rhopressa & Rocklatan), Europe, and Japan. While at Bayer, she launched EYLEA successfully into a blockbuster brand.
She is currently a board member to Curative Bio and an advisor to Paratus Sciences, EyeDura Therapeutics and OmniPulse Biosciences.
Theresa received her medical degree from Guy’s Kings and St. Thomas’ School of Medicine, King’s College, University of London and her Executive Master’s in business administration from the European School of Management & Technology (ESMT), Berlin.
